A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION

Chrysalis Biotherapeutics公司是使用天然肽再生信号来恢复正常干细胞群的先驱，以防止损伤、缺血和辐射造成的长期损害。在这份合同中，他们将进一步开发他们的产品TP508，一种凝血酶肽，通过在已建立的急性辐射和延迟效应的小鼠和猪模型中获得疗效数据、病理生理和药物计量学数据，以支持动物法规IND和许可，并在该项目结束时启动关键的动物研究。TP508是一种已经用于皮肤和肌肉骨骼修复的人体临床试验的改造产品。

Chrysalis Biotherapeutics, Inc. is pioneering the use of natural peptide regenerative signals that restore normal stem cell populations to prevent long-term damage from injury, ischemia, and radiation. In this contract they will further develop their product, TP508, a thrombin peptide by obtaining efficacy data, pathophysiological and pharmacometric data in established murine and porcine models of acute and delayed effects of acute radiation to support Animal Rule IND and licensure and initiate pivotal animal studies at the end of this project. TP508 is a repurposed product already in human clinical trials for dermal and musculoskeletal repair.